By Sabela OjeaExelixis has filed a complaint for an alleged patent infringement against Cipla and its abbreviated new drug application that is now pending with the Food and Drug Administration. Exelixis is also requesting and equitable relief enjoining Cipla from infringing its patents, the company said. Cipla's abbreviated new drug application now requests approval to market generic versions of its anti-cancer treatment Cabometyx in tablets with 20 milligrams and 40 milligrams dosage strengths prior to the expiration of some patents. The company on Thursday filed the complaint in the U.S. District Court for the District of Delaware. Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix(END) Dow Jones Newswires05-10-24 1718ET

Source: Wall Street Journal May 11, 2024 09:22 UTC